Pub Date : 2020-01-01DOI: 10.35248/2155-9570.20.11.828
Tie Zhao
The Human Immunodeficiency Virus-1 (HIV-1) envelope protein gp120 is the major contributor to the pathogenesis of retinopathy and uveitis in HIV-1-related eye diseases. Disruption of the structure and function of the Blood-Retina Barrier (BRB) is the major contributor of HIV-1-related eye diseases and the molecular mechanism remains unknown. Our mini review revealed that retinopathy and uveitis are required for gp120- induced inflammation and epigenetic changes and suggest that gp120 regulate tight junction protein.
{"title":"HIV Associated Eye Diseases: Existing Cognitive and Possible Mechanisms","authors":"Tie Zhao","doi":"10.35248/2155-9570.20.11.828","DOIUrl":"https://doi.org/10.35248/2155-9570.20.11.828","url":null,"abstract":"The Human Immunodeficiency Virus-1 (HIV-1) envelope protein gp120 is the major contributor to the pathogenesis of retinopathy and uveitis in HIV-1-related eye diseases. Disruption of the structure and function of the Blood-Retina Barrier (BRB) is the major contributor of HIV-1-related eye diseases and the molecular mechanism remains unknown. Our mini review revealed that retinopathy and uveitis are required for gp120- induced inflammation and epigenetic changes and suggest that gp120 regulate tight junction protein.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"3 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84300467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.35248/2155-9570.20.11.848
E. Klug, Marika Chachanidze, Abraham Nirappel, N. Hall, T. C. Chang, David Sol -Del Valle
Objective: There is controversy surrounding the next best step in treating plateau iris syndrome (PIS) patients with persistent angle dysfunction despite a patent laser peripheral iridotomy (LPI). The aim of this study was to examine the effectiveness of argon laser peripheral iridoplasty (ALPI) in PIS patients with a patent LPI. Methods: Retrospective review of medical records in consecutive patients that underwent ALPI to treat persistently narrow angles due to underlying PIS after a patent LPI. Patients in whom angle configuration could not be ascertained by review of medical records, those with less than 12 months follow-up at our institution, or those younger than 18 years of age were excluded. Kaplan-Meier survival analysis was used to determine treatment survival time. Paired t-tests were used to compare intraocular pressure (IOP), number of glaucoma medications, and bestcorrected visual acuity (BCVA) 12 months post-ALPI and at the last follow-up visit. Results: Fifty-one eyes of 51 patients were included in the analysis. The median survival time for a successful ALPI procedure was 1023 days (34.1 months). The majority of failure events were attributed to cataract extraction to open a persistently narrow angle, performed at approximately 934 (± 694) days (31.1 months) after ALPI. No changes in IOP, number of glaucoma medications, or BCVA from baseline were observed after 12 months or at last follow-up. Conclusion: ALPI is a potentially effective treatment for PIS following LPI. While angle dysfunction may re-emerge over time, ALPI can potentially delay the need for lensectomy in patients without visually significant cataracts.
{"title":"Effectiveness of Argon Laser Peripheral Iridoplasty in Plateau Iris Syndrome Patients after Laser Peripheral Iridotomy","authors":"E. Klug, Marika Chachanidze, Abraham Nirappel, N. Hall, T. C. Chang, David Sol -Del Valle","doi":"10.35248/2155-9570.20.11.848","DOIUrl":"https://doi.org/10.35248/2155-9570.20.11.848","url":null,"abstract":"Objective: There is controversy surrounding the next best step in treating plateau iris syndrome (PIS) patients with persistent angle dysfunction despite a patent laser peripheral iridotomy (LPI). The aim of this study was to examine the effectiveness of argon laser peripheral iridoplasty (ALPI) in PIS patients with a patent LPI. Methods: Retrospective review of medical records in consecutive patients that underwent ALPI to treat persistently narrow angles due to underlying PIS after a patent LPI. Patients in whom angle configuration could not be ascertained by review of medical records, those with less than 12 months follow-up at our institution, or those younger than 18 years of age were excluded. Kaplan-Meier survival analysis was used to determine treatment survival time. Paired t-tests were used to compare intraocular pressure (IOP), number of glaucoma medications, and bestcorrected visual acuity (BCVA) 12 months post-ALPI and at the last follow-up visit. Results: Fifty-one eyes of 51 patients were included in the analysis. The median survival time for a successful ALPI procedure was 1023 days (34.1 months). The majority of failure events were attributed to cataract extraction to open a persistently narrow angle, performed at approximately 934 (± 694) days (31.1 months) after ALPI. No changes in IOP, number of glaucoma medications, or BCVA from baseline were observed after 12 months or at last follow-up. Conclusion: ALPI is a potentially effective treatment for PIS following LPI. While angle dysfunction may re-emerge over time, ALPI can potentially delay the need for lensectomy in patients without visually significant cataracts.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"29 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83541274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.35248/2155-9570.20.11.852
C. Roșca
A 57-year-old male patient operated 5 years before for cataract, arrives in our emergency service complaining of sudden decrease of the visual acuity of the left eye. Slit lamp examination reveals aphakia, iridodonesis and nonreflective semi-mydriatic pupil. Volk ® lens examination of the fundus shows dislocation of the entire bag-IOL complex into the vitreous. Our approach was: pars plana posterior vitrectomy, IOL-capsular bag complex extraction and implantation of an iris-claw artificial IOL with good anatomical and functional results. Iris-Claw artificial IOL’s are in the authors’ opinion a good and less invasive method for treating afakia of any cause.
{"title":"Retro Pupillary Iris-Claw IOL the Treatment for Traumatic IOL Capsular Bag Complex Dislocation","authors":"C. Roșca","doi":"10.35248/2155-9570.20.11.852","DOIUrl":"https://doi.org/10.35248/2155-9570.20.11.852","url":null,"abstract":"A 57-year-old male patient operated 5 years before for cataract, arrives in our emergency service complaining of sudden decrease of the visual acuity of the left eye. Slit lamp examination reveals aphakia, iridodonesis and nonreflective semi-mydriatic pupil. Volk ® lens examination of the fundus shows dislocation of the entire bag-IOL complex into the vitreous. Our approach was: pars plana posterior vitrectomy, IOL-capsular bag complex extraction and implantation of an iris-claw artificial IOL with good anatomical and functional results. Iris-Claw artificial IOL’s are in the authors’ opinion a good and less invasive method for treating afakia of any cause.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"8 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89943193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
1Undergraduate Student of Medicine, UnP Potiguar University, Laureate International Universities, Natal, Brazil 2Postgraduate Program in Biotechnology at Potiguar University/ UnP Laureate International Universities, Natal, Brazil. Ph.D. Health Science, Natal, RN, Brazil 3Postgraduate Program in Biotechnology, Potiguar University/ UnP Laureate International Universities, Full Professor Department of Surgery, Federal University of Rio Grande do Norte. Full Professor, Department of Surgery, Potiguar University, Ph.D, Health Science, Natal, RN, Brazil More Information
{"title":"Dry eye syndrome: Therapeutic challenges and future trends","authors":"Araújo-Neto Irami, Rêgo Amália Cinhtia Meneses, Araújo-Filho* Irami","doi":"10.29328/journal.ijceo.1001023","DOIUrl":"https://doi.org/10.29328/journal.ijceo.1001023","url":null,"abstract":"1Undergraduate Student of Medicine, UnP Potiguar University, Laureate International Universities, Natal, Brazil 2Postgraduate Program in Biotechnology at Potiguar University/ UnP Laureate International Universities, Natal, Brazil. Ph.D. Health Science, Natal, RN, Brazil 3Postgraduate Program in Biotechnology, Potiguar University/ UnP Laureate International Universities, Full Professor Department of Surgery, Federal University of Rio Grande do Norte. Full Professor, Department of Surgery, Potiguar University, Ph.D, Health Science, Natal, RN, Brazil More Information","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"103 1","pages":"030-034"},"PeriodicalIF":0.0,"publicationDate":"2019-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79084386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jina V Han, Dipika V. Patel, Kevin Liu, Bia Z. Kim, T. Sherwin, C. McGhee
Reduction of intraoperative complications in phacoemulsification cataract surgery.
白内障超声乳化手术术中并发症的减少。
{"title":"Auckland Cataract Study IV: Practical application of NZCRS cataract risk stratification to reduce phacoemulsification complications","authors":"Jina V Han, Dipika V. Patel, Kevin Liu, Bia Z. Kim, T. Sherwin, C. McGhee","doi":"10.1111/ceo.13696","DOIUrl":"https://doi.org/10.1111/ceo.13696","url":null,"abstract":"Reduction of intraoperative complications in phacoemulsification cataract surgery.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"29 1","pages":"311 - 318"},"PeriodicalIF":0.0,"publicationDate":"2019-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85219995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
argued that even when severe, they cause very few person-years of morbidity if implanted in elderly patients. Multifocal lenses, however, are frequently implanted in middle-aged people, when the longer time in situ may result in more severe and significant grades of glistenings. Sometimes laser assisted enhancement is required in order to achieve optimal refractive outcome. This puts patients at risk of dry eye which will exacerbate the optical aberrations of a multifocal IOL if glistenings occur. Surgeons may reflect on the life expectancy of patients receiving these lenses as well as the increasing prevalence of dry eye with age. Non-chromophore lenses may be a prudent choice for young patients, particularly given the apparent absence of benefit found in recent major reviews. In the presence of severe glistenings, IOL exchange should be considered before a posterior capsulotomy is performed.
{"title":"Cardiovascular effects and safety of mannitol in treating raised intraocular pressure","authors":"Alp Atik, Elsie Chan, C. Crock, G. S. Ang","doi":"10.1111/ceo.13695","DOIUrl":"https://doi.org/10.1111/ceo.13695","url":null,"abstract":"argued that even when severe, they cause very few person-years of morbidity if implanted in elderly patients. Multifocal lenses, however, are frequently implanted in middle-aged people, when the longer time in situ may result in more severe and significant grades of glistenings. Sometimes laser assisted enhancement is required in order to achieve optimal refractive outcome. This puts patients at risk of dry eye which will exacerbate the optical aberrations of a multifocal IOL if glistenings occur. Surgeons may reflect on the life expectancy of patients receiving these lenses as well as the increasing prevalence of dry eye with age. Non-chromophore lenses may be a prudent choice for young patients, particularly given the apparent absence of benefit found in recent major reviews. In the presence of severe glistenings, IOL exchange should be considered before a posterior capsulotomy is performed.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"83 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82945436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hassan Hassan, R. Epstein, S. Cherepanoff, R. Conway
Conjunctival melanoma (CM) comprises 2% to 5% of all ocular tumours, and 5% to 7% of ocular melanomas. The annual incidence of CM is 0.2 to 0.8 per million amongst Caucasians, in which population the usual age range of presentation is 55 to 65 years. The standard of care for the initial management of localized CM is no-touch surgical excision with a minimum 2 to 4 mm margin. Locally advanced disease involving orbit invasion is more challenging to manage and has traditionally been regarded as an indication for radical curative-intent surgery (orbital exenteration). Here we report a case of locally advanced and recurrent CM that has been managed successfully for the last 3.5 years using systemic targeted therapy. A 53-year-old Caucasian male presented in January 2016 to the ocular oncology unit with a biopsy confirming locally advanced CM (AJCC stage T3B) of the right eye invading the anterior orbit and upper tarsal plate. The tumour had been excised in December 2015. Visual acuities were 6/7.5 and 6/6 in the right and left eye, respectively. Staging investigations including fluorodeoxyglucosepositron emission tomography scanning revealed no metastatic disease. Mutation testing (Ion Torrent Ampliseq Cancer Gene Panel v2.0) of formalin-fixed paraffin-embedded tissue confirmed a classical BRAF (V600E) mutation. During the multidisciplinary discussion, three aspects of the patient's own preferences were identified: first, ocular removal may affect his employment as a licensed occupational operator of heavy equipment; second, satisfactory binocular vision as an enthusiastic recreational cricket player; and third, importance of normal cosmesis for lifestyle reasons. On the other hand, it was explained to the patient that surgical exenteration could well represent the only plausible curative intervention. Against that reasoning, however, it was also conceded that even proceeding to exenteration would not guarantee a cure, since subsequent locoregional and/or metastatic recurrence remained a possibility. After informed discussion and consent, the patient was offered initial management using systemic therapy targeting V600E-mutant BRAF, consisting of dabrafenib and trametinib. Patient understood that the provisional plan would be for substitution of immunotherapy (eg, anti-PD1 plus ipilimumab) with the aim of achieving a further period of long-term control, albeit not necessarily a cure. The possibility of using initial immunotherapy was also discussed, though it was pointed out that a rapid initial tumour shrinkage might be more reliably achieved using mutation-targeting kinase inhibitors, and hence this approach was chosen. Fortunately, a complete clinical and radiologic remission of disease was evident by April 2016 (Figure 1A,B). From May 2016, the clinical course was complicated by drug-related fever and abnormal liver function tests, which was at first managed with a combination of treatment delay, dose reduction, and/or steroid cover. A small recurr
{"title":"Effective conservative management of locally advanced conjunctival melanoma using initial systemic therapy","authors":"Hassan Hassan, R. Epstein, S. Cherepanoff, R. Conway","doi":"10.1111/ceo.13691","DOIUrl":"https://doi.org/10.1111/ceo.13691","url":null,"abstract":"Conjunctival melanoma (CM) comprises 2% to 5% of all ocular tumours, and 5% to 7% of ocular melanomas. The annual incidence of CM is 0.2 to 0.8 per million amongst Caucasians, in which population the usual age range of presentation is 55 to 65 years. The standard of care for the initial management of localized CM is no-touch surgical excision with a minimum 2 to 4 mm margin. Locally advanced disease involving orbit invasion is more challenging to manage and has traditionally been regarded as an indication for radical curative-intent surgery (orbital exenteration). Here we report a case of locally advanced and recurrent CM that has been managed successfully for the last 3.5 years using systemic targeted therapy. A 53-year-old Caucasian male presented in January 2016 to the ocular oncology unit with a biopsy confirming locally advanced CM (AJCC stage T3B) of the right eye invading the anterior orbit and upper tarsal plate. The tumour had been excised in December 2015. Visual acuities were 6/7.5 and 6/6 in the right and left eye, respectively. Staging investigations including fluorodeoxyglucosepositron emission tomography scanning revealed no metastatic disease. Mutation testing (Ion Torrent Ampliseq Cancer Gene Panel v2.0) of formalin-fixed paraffin-embedded tissue confirmed a classical BRAF (V600E) mutation. During the multidisciplinary discussion, three aspects of the patient's own preferences were identified: first, ocular removal may affect his employment as a licensed occupational operator of heavy equipment; second, satisfactory binocular vision as an enthusiastic recreational cricket player; and third, importance of normal cosmesis for lifestyle reasons. On the other hand, it was explained to the patient that surgical exenteration could well represent the only plausible curative intervention. Against that reasoning, however, it was also conceded that even proceeding to exenteration would not guarantee a cure, since subsequent locoregional and/or metastatic recurrence remained a possibility. After informed discussion and consent, the patient was offered initial management using systemic therapy targeting V600E-mutant BRAF, consisting of dabrafenib and trametinib. Patient understood that the provisional plan would be for substitution of immunotherapy (eg, anti-PD1 plus ipilimumab) with the aim of achieving a further period of long-term control, albeit not necessarily a cure. The possibility of using initial immunotherapy was also discussed, though it was pointed out that a rapid initial tumour shrinkage might be more reliably achieved using mutation-targeting kinase inhibitors, and hence this approach was chosen. Fortunately, a complete clinical and radiologic remission of disease was evident by April 2016 (Figure 1A,B). From May 2016, the clinical course was complicated by drug-related fever and abnormal liver function tests, which was at first managed with a combination of treatment delay, dose reduction, and/or steroid cover. A small recurr","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90502700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Rowland, Graham A. Lee, Shabbir Mohamed, P. Shah
1. Ramenaden ER, Raiji VR. Clinical characteristics and visual outcomes in infectious scleritis: a review. Clin Ophthalmol. 2013;7: 2113-2122. 2. Oguz H, Sobaci G. The use of hyperbaric oxygen therapy in ophthalmology. Surv Ophthalmol. 2008;53(2):112-120. 3. Locher DH, Adesina A, Wolf TC, Imes CB, Chodosh J. Postoperative Rhizopus scleritis in a diabetic man. J Cataract Refract Surg. 1998;24(4):562-565. 4. Chong R, Ayer CJ, Francis IC, Coroneo MT, Wolfers DL. Adjunctive hyperbaric oxygen in pseudomonas keratitis. Br J Ophthalmol. 2007;91(4):560-561. 5. Bayer A, Mutlu FM, Sobaci G. Hyperbaric oxygen therapy for mitomycin C-induced scleral necrosis. Ophthalmic Surg Lasers. 2002;33(1):58-61.
1. Ramenaden ER, Raiji VR。传染性巩膜炎的临床特点和视觉效果:综述。中华眼科杂志，2013;7:2113-2122。2. 王志强，王志强。高压氧治疗在眼科中的应用。中华眼科杂志，2008;33(2):112-120。3.Locher DH, Adesina A, Wolf TC, Imes CB, Chodosh J.糖尿病患者术后根霉性巩膜炎1例。[J]中华白内障杂志，1998;24(4):562-565。4. Chong R, Ayer CJ, Francis IC, Coroneo MT, Wolfers DL。假单胞菌性角膜炎的辅助高压氧治疗。中华眼科杂志，2007;31(4):556 -561。5. 张建军，张建军，张建军，等。高压氧治疗丝裂霉素所致巩膜坏死的临床观察。眼科激光手术。2002;33(1):58-61。
{"title":"Progressive intraluminal stent migration into the anterior chamber","authors":"C. Rowland, Graham A. Lee, Shabbir Mohamed, P. Shah","doi":"10.1111/ceo.13692","DOIUrl":"https://doi.org/10.1111/ceo.13692","url":null,"abstract":"1. Ramenaden ER, Raiji VR. Clinical characteristics and visual outcomes in infectious scleritis: a review. Clin Ophthalmol. 2013;7: 2113-2122. 2. Oguz H, Sobaci G. The use of hyperbaric oxygen therapy in ophthalmology. Surv Ophthalmol. 2008;53(2):112-120. 3. Locher DH, Adesina A, Wolf TC, Imes CB, Chodosh J. Postoperative Rhizopus scleritis in a diabetic man. J Cataract Refract Surg. 1998;24(4):562-565. 4. Chong R, Ayer CJ, Francis IC, Coroneo MT, Wolfers DL. Adjunctive hyperbaric oxygen in pseudomonas keratitis. Br J Ophthalmol. 2007;91(4):560-561. 5. Bayer A, Mutlu FM, Sobaci G. Hyperbaric oxygen therapy for mitomycin C-induced scleral necrosis. Ophthalmic Surg Lasers. 2002;33(1):58-61.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86210781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
for advanced local and systemic conjunctival melanoma: a clinical case series. J Immunother Cancer. 2019;7(1):83. https://doi. org/10.1186/s40425-019-0555-7. 4. Lake SL, Jmor F, Dopierala J, Taktak AFG, Coupland SE, Damato BE. Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes. Invest Ophthalmol Vis Sci. 2011;52:5598. https://doi.org/10.1167/iovs.10-6934. 5. Griewank KG, Westekemper H, Murali R, et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res. 2013;19:3143-3152. https://doi.org/10.1158/1078-0432.CCR-130163.
{"title":"Novel use of adjunctive hyperbaric therapy for fungal scleritis","authors":"Harry Yip, Elsie Chan","doi":"10.1111/ceo.13689","DOIUrl":"https://doi.org/10.1111/ceo.13689","url":null,"abstract":"for advanced local and systemic conjunctival melanoma: a clinical case series. J Immunother Cancer. 2019;7(1):83. https://doi. org/10.1186/s40425-019-0555-7. 4. Lake SL, Jmor F, Dopierala J, Taktak AFG, Coupland SE, Damato BE. Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes. Invest Ophthalmol Vis Sci. 2011;52:5598. https://doi.org/10.1167/iovs.10-6934. 5. Griewank KG, Westekemper H, Murali R, et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res. 2013;19:3143-3152. https://doi.org/10.1158/1078-0432.CCR-130163.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"45 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84680403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Familial exudative vitreoretinopathy (FEVR, OMIM 133780) is a severe hereditary retinal disease characterized by incomplete retinal vascular development and pathological neovascularization. It has been reported that variants in nine genes are associated with FEVR, but they can only explain approximately 50% of FEVR patients, suggesting that other FEVR‐associated variants or genes remain to be discovered.
{"title":"Identification of novel variants in the FZD4 gene associated with familial exudative vitreoretinopathy in Chinese families","authors":"Huijuan Xu, Shanshan Zhang, Lulin Huang, Peiquan Zhao, Xiang Zhang, Zhenglin Yang, Lin Zhang","doi":"10.1111/ceo.13690","DOIUrl":"https://doi.org/10.1111/ceo.13690","url":null,"abstract":"Familial exudative vitreoretinopathy (FEVR, OMIM 133780) is a severe hereditary retinal disease characterized by incomplete retinal vascular development and pathological neovascularization. It has been reported that variants in nine genes are associated with FEVR, but they can only explain approximately 50% of FEVR patients, suggesting that other FEVR‐associated variants or genes remain to be discovered.","PeriodicalId":15372,"journal":{"name":"Journal of Clinical & Experimental Ophthalmology","volume":"1967 1","pages":"356 - 365"},"PeriodicalIF":0.0,"publicationDate":"2019-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91398227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：